FLASH irradiation reduces astrocyte injury but intensifies glioma metabolic stress in vitro

At 8 Gy, astrocyte injury was approximately 35% with FLASH versus 65% with conventional irradiation, alongside persistent glioma-cell metabolic stress.

KEY POINTS

  • This preclinical study compared ultra-high-dose-rate FLASH irradiation with conventional-dose-rate irradiation in three experimental models: primary healthy murine cortical astrocytes, the murine GL261 glioma cell line, and human U87 glioblastoma cells. Investigators assessed reactive oxygen species (ROS), mitochondrial membrane potential, respiratory function, cell-cycle progression, cell-death-associated markers, and transcriptional stress responses. Most mechanistic experiments used a single dose of 8 Gy, with additional experiments at 4 and 16 Gy.
  • Both irradiation conditions were delivered using the same 9-MeV electron linear accelerator, minimizing differences unrelated to dose rate. FLASH used an average dose rate of 240 Gy/s, with 1 Gy per pulse and 4-μs pulse duration, compared with conventional irradiation at 6 Gy/min (0.1 Gy/s) and 0.02 Gy per pulse. This controlled comparison isolated early cellular responses to the selected dose-rate conditions, rather than testing multiple FLASH delivery configurations.
  • Healthy astrocytes showed reduced acute oxidative stress and cellular injury after FLASH. Following 8 Gy, the initial ROS peak was significantly lower than after conventional irradiation, while nuclear condensation and fragmentation assessed at 72 hours indicated approximately 35% cell injury with FLASH versus 65% with conventional irradiation. The analysis included three independent experiments, with the between-modality difference statistically significant (p<0.05). These cellular findings do not directly establish preserved brain tissue function.
  • FLASH-treated astrocytes demonstrated relative preservation of mitochondrial function. At selected post-irradiation time points, FLASH was associated with greater mitochondrial membrane potential and lower oxidative stress, while Seahorse bioenergetic analysis showed higher spare respiratory capacity and lower proton leak compared with conventional irradiation. FLASH also produced stronger and sustained p21 transcriptional induction, with a later trend toward increased p16, suggesting activation of stress-response programs without directly proving cellular senescence.
  • Glioma cells showed a different pattern of oxidative and proliferative stress. In GL261 cells, FLASH produced a lower immediate ROS peak but a greater subsequent ROS accumulation rate than conventional irradiation. Both modalities reduced colony formation in a dose-dependent manner, while Annexin V positivity at 72 hours after 8 Gy was comparable between treatments. However, FLASH induced greater G2/M accumulation at 24 hours, suggesting altered cell-cycle progression rather than a demonstrated increase in apoptotic cell death.
  • FLASH caused more persistent mitochondrial dysfunction in GL261 cells. At 24–72 hours, FLASH-treated cells showed greater loss of mitochondrial membrane potential, continued oxidative stress, and stronger suppression of basal, ATP-linked, and maximal respiration than conventionally irradiated cells. Pharmacological interventions using DPQ, Necrostatin-1, Calpeptin, and zVAD produced modality-dependent changes in respiratory parameters, suggesting possible contributions from PARP-, necroptosis-, calpain-, and caspase-associated signaling. These inhibitor responses do not establish definitive activation of specific regulated cell-death pathways.
  • Human U87 glioblastoma cells showed additional evidence of FLASH-associated metabolic stress. After 8 Gy, FLASH produced greater Annexin V positivity at 72 hours and higher intracellular ROS accumulation at 24 hours than conventional irradiation, accompanied by altered NAD⁺ levels and suppression of mitochondrial respiration. However, these findings were obtained in established cell lines with generally three to four independent experiments per assay. The study lacked patient-derived tumor models, three-dimensional tissue architecture, immune interactions, and in-vivo assessment of brain toxicity or tumor control.

CLINICAL TAKEAWAY

FLASH irradiation produced distinct early redox and mitochondrial responses in healthy astrocytes and glioma cells, suggesting a potential biological basis for differential normal-tissue and tumor-cell adaptation. However, these are controlled in-vitro mechanistic observations and do not establish improved glioblastoma control, durable normal-brain protection, or a clinically effective FLASH treatment strategy.

SOURCE

Cell Death Discovery

Browse more research Suggest a correction